Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$2.87 +0.7%	$2.78	$2.20 ▼ $5.80	$283.76M	2.59	1.52 million shs	669,185 shs
CURR CURRENC Group	$1.53 -1.3%	$1.82	$1.19 ▼ $7.08	$71.19M	-0.17	2.24 million shs	55,658 shs
CYDY CytoDyn	$0.23 +0.1%	$0.24	$0.10 ▼ $0.49	$284.32M	1.33	3.13 million shs	1.95 million shs
ITOS iTeos Therapeutics	$7.35 -1.5%	$6.59	$4.80 ▼ $18.75	$280.73M	1.43	480,190 shs	343,865 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	0.00%	+14.34%	-10.59%	-7.12%	-26.41%
CURR CURRENC Group	0.00%	-0.65%	+1.32%	-16.39%	+152,999,900.00%
CYDY CytoDyn	0.00%	+13.09%	-3.47%	+3.45%	+55.35%
ITOS iTeos Therapeutics	0.00%	+12.90%	+9.70%	-3.80%	-30.46%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AQST Aquestive Therapeutics	1.552 of 5 stars	3.6	2.0	0.0	0.0	2.4	0.0	0.0
CURR CURRENC Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CYDY CytoDyn	0.0319 of 5 stars	0.0	2.0	0.0	0.0	0.0	0.0	0.0
ITOS iTeos Therapeutics	2.4206 of 5 stars	3.5	1.0	0.0	0.0	3.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	3.14	Buy	$10.67	271.66% Upside
CURR CURRENC Group	3.50	Strong Buy	$3.50	128.76% Upside
CYDY CytoDyn	0.00	N/A	N/A	N/A
ITOS iTeos Therapeutics	3.00	Buy	$25.75	250.34% Upside

Current Analyst Ratings Breakdown

Latest CURR, CYDY, AQST, and ITOS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/2/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/10/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/7/2025	AQST Aquestive Therapeutics	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$7.00
3/7/2025	AQST Aquestive Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/7/2025	AQST Aquestive Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $8.00
3/6/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$19.00 ➝ $17.00
3/6/2025	ITOS iTeos Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$22.00 ➝ $15.00
3/6/2025	ITOS iTeos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
3/5/2025	CURR CURRENC Group	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$3.50
3/5/2025	CURR CURRENC Group	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/5/2025	CURR CURRENC Group	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$3.50

(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$57.56M	4.93	N/A	N/A	($1.59) per share	-1.81
CURR CURRENC Group	$46.44M	1.53	N/A	N/A	N/A	∞
CYDY CytoDyn	$270K	1,053.05	N/A	N/A	($0.11) per share	-2.10
ITOS iTeos Therapeutics	$35M	8.02	N/A	N/A	$16.08 per share	0.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$7.87M	-$0.52	N/A	N/A	N/A	-59.75%	N/A	-33.96%	5/6/2025 (Estimated)
CURR CURRENC Group	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	7/14/2025 (Estimated)
CYDY CytoDyn	-$49.84M	-$0.01	N/A	∞	N/A	N/A	N/A	-76.70%	N/A
ITOS iTeos Therapeutics	-$112.64M	-$3.31	N/A	N/A	N/A	N/A	-20.11%	-17.50%	5/9/2025 (Estimated)

Latest CURR, CYDY, AQST, and ITOS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2025	Q1 2025	ITOS iTeos Therapeutics	-$0.94	N/A	N/A	N/A	$1.80 million	N/A
5/6/2025	Q1 2025	AQST Aquestive Therapeutics	-$0.17	N/A	N/A	N/A	$12.23 million	N/A
4/14/2025	Q4 2024	CURR CURRENC Group	-$0.04	-$0.70	-$0.66	-$0.70	$10.50 million	$11.07 million
3/5/2025	Q4 2024	AQST Aquestive Therapeutics	-$0.14	-$0.19	-$0.05	-$0.19	$13.11 million	$11.87 million
3/5/2025	Q4 2024	ITOS iTeos Therapeutics	-$1.14	-$1.01	+$0.13	-$1.01	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
CURR CURRENC Group	N/A	N/A	N/A	N/A	N/A
CYDY CytoDyn	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	6.37	5.91
CURR CURRENC Group	N/A	N/A	N/A
CYDY CytoDyn	N/A	0.35	0.35
ITOS iTeos Therapeutics	N/A	14.80	14.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
CURR CURRENC Group	56.01%
CYDY CytoDyn	5.06%
ITOS iTeos Therapeutics	97.16%

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	7.85%
CURR CURRENC Group	17.80%
CYDY CytoDyn	0.54%
ITOS iTeos Therapeutics	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	160	98.87 million	84.02 million	Optionable
CURR CURRENC Group	2	46.53 million	38.25 million	N/A
CYDY CytoDyn	20	1.23 billion	1.22 billion	Not Optionable
ITOS iTeos Therapeutics	90	38.19 million	31.97 million	Optionable

CURR, CYDY, AQST, and ITOS Headlines

Recent News About These Companies

Eversept Partners LP Buys New Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

April 24 at 7:09 AM | marketbeat.com

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Short Interest Update

April 21, 2025 | marketbeat.com

Renaissance Technologies LLC Boosts Stock Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

April 21, 2025 | marketbeat.com

Positive week for iTeos Therapeutics, Inc. (NASDAQ:ITOS) institutional investors who lost 38% over the past year

April 19, 2025 | finance.yahoo.com

Why iTeos Therapeutics, Inc.’s (ITOS) Stock Is Up 7.59%

April 16, 2025 | aaii.com

ExodusPoint Capital Management LP Invests $677,000 in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

April 14, 2025 | marketbeat.com

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Acquired by JPMorgan Chase & Co.

April 14, 2025 | marketbeat.com

Trexquant Investment LP Has $1.38 Million Stock Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

April 12, 2025 | marketbeat.com

ADAR1 Capital Management LLC Has $1.01 Million Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

April 9, 2025 | marketbeat.com

Raymond James Financial Inc. Buys New Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

April 5, 2025 | marketbeat.com

iTeos Therapeutics (ITOS) Gets a Buy from Piper Sandler

March 31, 2025 | markets.businessinsider.com

iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025

March 25, 2025 | globenewswire.com

Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet

March 13, 2025 | msn.com

iTeos Therapeutics price target lowered to $17 from $19 at Wells Fargo

March 7, 2025 | markets.businessinsider.com

iTeos Therapeutics Full Year 2024 Earnings: In Line With Expectations

March 6, 2025 | finance.yahoo.com

iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

March 5, 2025 | globenewswire.com

iTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success Nevertheless

February 27, 2025 | seekingalpha.com

ITOS stock touches 52-week low at $7.09 amid market challenges

February 11, 2025 | msn.com

We Think iTeos Therapeutics (NASDAQ:ITOS) Needs To Drive Business Growth Carefully

February 4, 2025 | finance.yahoo.com

(ITOS) Proactive Strategies

January 27, 2025 | news.stocktradersdaily.com

5 US Longevity and Anti-aging Stocks to Watch in 2025

January 24, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Could Palantir’s Latest Partnership Set a Base for a Move Higher?
By Chris Markoch | April 23, 2025
View Could Palantir’s Latest Partnership Set a Base for a Move Higher?
3 Safe Dividend Stocks as Investors Seek to Reset Diversification
By Chris Markoch | April 14, 2025
View 3 Safe Dividend Stocks as Investors Seek to Reset Diversification
3 Stocks to Buy Now for Tariff Immunity
By Gabriel Osorio-Mazilli | April 23, 2025
View 3 Stocks to Buy Now for Tariff Immunity
Coca-Cola Stock Looks Refreshing After the Relief Rally
By Chris Markoch | April 13, 2025
View Coca-Cola Stock Looks Refreshing After the Relief Rally
3 Bond ETFs for the Diversified Investor
By Chris Markoch | April 13, 2025
View 3 Bond ETFs for the Diversified Investor

CURR, CYDY, AQST, and ITOS Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$2.87 +0.02 (+0.70%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$2.91 +0.04 (+1.39%)

As of 04/25/2025 07:38 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

CURRENC Group NASDAQ:CURR

$1.53 -0.02 (-1.29%)

Closing price 04/25/2025 03:59 PM Eastern

Extended Trading

$1.52 -0.01 (-0.65%)

As of 04/25/2025 07:18 PM Eastern

Currenc Group, Inc. engages in operating a fintech banking platform. It operates through the following segments: Remittance Services, Sales of Airtime, and Other Services. The company is headquartered in Singapore.

CytoDyn OTCMKTS:CYDY

$0.23 +0.00 (+0.09%)

As of 04/25/2025 03:59 PM Eastern

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

iTeos Therapeutics NASDAQ:ITOS

$7.35 -0.11 (-1.47%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$7.35 0.00 (0.00%)

As of 04/25/2025 07:57 PM Eastern

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time